(Q40231174)

English

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

scientific article published on 20 April 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Ignacio Melero, MD-PhD

21

object named as

Ignacio Melero

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Anthony B El-Khoueiry

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Todd S Crocenzi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Chiun Hsu

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Tae-You Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Su-Pin Choo

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jörg Trojan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Theodore H Welling

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Tim Meyer

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Yoon-Koo Kang

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Akhil Chopra

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jeffrey Anderson

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Christine Dela Cruz

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Lixin Lang

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jaclyn Neely

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Hao Tang

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Homa B Dastani

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Masatoshi Kudo

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

0 references

publication date

20 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

389

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

10088

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

2492-2502

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging Opportunities and Challenges in Cancer Immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune checkpoint blockade: a common denominator approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological landscape and immunotherapy of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential of immunotherapy for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)31046-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40231174&oldid=1889634057"